Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors

Abstract

Background and Purpose Orbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective. Methods We reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment. Results The three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation. Conclusions Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.

Orbital inflammatory pseudotumor: new advances in diagnosis, pathogenesis, and treatment

“…The might side effects are hypertension, neurotoxicity, diabetes, and nephrotoxicity [ 103 – 106 ]. Hyun Jae Kim et al reported that tacrolimus may be a secure and efficient immunosuppressant for the treatment of refractory or relapsed OIP [ 107 ].…”